These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 30953540)

  • 41. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
    Nash P; Coates LC; Kivitz AJ; Mease PJ; Gladman DD; Covarrubias-Cobos JA; FitzGerald O; Fleishaker D; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Romero AB; Kanik KS
    Rheumatol Ther; 2020 Sep; 7(3):553-580. PubMed ID: 32506317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
    Song GG; Bae SC; Lee YH
    Korean J Intern Med; 2014 Sep; 29(5):656-63. PubMed ID: 25228842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
    Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Wang L; Chen C; Kwok K; Biswas P; Shapiro A; Madsen A; Wollenhaupt J
    RMD Open; 2020 Oct; 6(3):. PubMed ID: 33127856
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
    Charles-Schoeman C; Wicker P; Gonzalez-Gay MA; Boy M; Zuckerman A; Soma K; Geier J; Kwok K; Riese R
    Semin Arthritis Rheum; 2016 Dec; 46(3):261-271. PubMed ID: 27443588
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
    McInnes IB; Kim HY; Lee SH; Mandel D; Song YW; Connell CA; Luo Z; Brosnan MJ; Zuckerman A; Zwillich SH; Bradley JD
    Ann Rheum Dis; 2014 Jan; 73(1):124-31. PubMed ID: 23482473
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
    Castañeda OM; Romero FJ; Salinas A; Citera G; Mysler E; Rillo O; Radominski SC; Cardiel MH; Jaller JJ; Alvarez-Moreno C; Ponce de Leon D; Castelli G; García EG; Kwok K; Rojo R
    J Clin Rheumatol; 2017 Jun; 23(4):193-199. PubMed ID: 28145906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis].
    Sonomoto K; Tanaka Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2015; 38(6):443-7. PubMed ID: 27118331
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
    Curtis JR; Zhang R; Krishnaswami S; Anisfeld A; Chen Y; Strengholt S; Chen C; Geier J
    Clin Rheumatol; 2017 Mar; 36(3):683-688. PubMed ID: 27470086
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
    Burmester GR; Curtis JR; Yun H; FitzGerald O; Winthrop KL; Azevedo VF; Rigby WFC; Kanik KS; Wang C; Biswas P; Jones T; Palmetto N; Hendrikx T; Menon S; Rojo R
    Drug Saf; 2020 Apr; 43(4):379-392. PubMed ID: 32006348
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
    Mease P; Charles-Schoeman C; Cohen S; Fallon L; Woolcott J; Yun H; Kremer J; Greenberg J; Malley W; Onofrei A; Kanik KS; Graham D; Wang C; Connell C; Valdez H; Hauben M; Hung E; Madsen A; Jones TV; Curtis JR
    Ann Rheum Dis; 2020 Nov; 79(11):1400-1413. PubMed ID: 32759265
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
    Calabrese LH; Abud-Mendoza C; Lindsey SM; Lee SH; Tatulych S; Takiya L; Iikuni N; Soma K; Luo Z; Fleischmann R
    Arthritis Care Res (Hoboken); 2020 Mar; 72(3):353-359. PubMed ID: 31207152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.
    Nash P; Coates LC; Fleishaker D; Kivitz AJ; Mease PJ; Gladman DD; FitzGerald O; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Kanik KS
    Lancet Rheumatol; 2021 Apr; 3(4):e270-e283. PubMed ID: 38279411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
    Strand V; Kremer J; Wallenstein G; Kanik KS; Connell C; Gruben D; Zwillich SH; Fleischmann R
    Arthritis Res Ther; 2015 Nov; 17():307. PubMed ID: 26530039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
    Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
    van der Heijde D; Strand V; Tanaka Y; Keystone E; Kremer J; Zerbini CAF; Cardiel MH; Cohen S; Nash P; Song YW; Tegzová D; Gruben D; Wallenstein G; Connell CA; Fleischmann R;
    Arthritis Rheumatol; 2019 Jun; 71(6):878-891. PubMed ID: 30666826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
    Pérez-Román DI; Ortiz-Haro AB; Ruiz-Medrano E; Contreras-Yáñez I; Pascual-Ramos V
    Rheumatol Int; 2018 Apr; 38(4):599-606. PubMed ID: 29264637
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
    Winthrop KL; Park SH; Gul A; Cardiel MH; Gomez-Reino JJ; Tanaka Y; Kwok K; Lukic T; Mortensen E; Ponce de Leon D; Riese R; Valdez H
    Ann Rheum Dis; 2016 Jun; 75(6):1133-8. PubMed ID: 26318385
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.
    Tanaka Y; Takeuchi T; Yamanaka H; Nakamura H; Toyoizumi S; Zwillich S
    Mod Rheumatol; 2015 Jul; 25(4):514-21. PubMed ID: 25496464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.